PharmExec Blog

Global Biosimilars Market to Soar to $24 Billion by 2019

Frost & Sullivan: Strong Pipeline of Monoclonal Antibodies (mAbs) Biosimilars in the US and Europe Lends Impetus to Global Market
The market is expected to soar from $1.2 billion of 2013 to $24 billion in 2019
LONDON – 29th January 2014 – The imminent entry of several companies, including big pharma, small biotech and generic participants, into the global biosimilars space will propel the market towards exponential growth. Already, Indian groups such as Dr. Reddy’s Laboratories, Biocon and Reliance Life Sciences are making a concerted effort to enter the European market. Although these companies have not yet penetrated the European market due to the stringent regulatory pathway, new product launches are expected in the mid-term.
Biosimilar markets in countries such as the U.S. and Japan are also expected to grow exponentially with more clarity on the regulatory pathway.
New research from Frost & Sullivan’s (http://www.lifesciences.frost.com) Analysis of the Global Biosimilars Market finds the market earned revenue of about $1.2 billion in 2013 and estimates this to reach approximately $24 billion in 2019. Untapped U.S. markets with a strong biosimilars pipeline as well as markets in Asia-Pacific and Latin America with a low cost of manufacturing will afford key growth opportunities.
“On one hand, the market is powering ahead regarding the strength of participants’ global expansion strategies, and, on the other, it is still beset by traditional patent-infringement issues,” said Frost & Sullivan Healthcare Senior Research Analyst K. Srinivas Sashidhar. “Moreover, the strategies adopted by innovator companies need to be taken into account. For instance, Johnson & Johnson has extended the European patent life of its innovator drug Remicade until February 2015, thereby delaying the launch of Hospira’s biosimilar monoclonal antibody (mAb) Inflectra and Celltrion’s biosimilar mAb Remsima.”
To further reduce the time to market, companies should also explore opportunities in mergers and acquisitions and alliances with companies having expertise in biosimilars manufacturing and development like Teva’s alliance with Cephalon and Lupin Pharmaceuticals’ alliance with Neuclone.
“In addition to mAbs, follitropins, interferons and low molecular weight heparins are likely to emerge in the long run,” added Sashidhar. “However, some companies may focus on specific therapeutic classes depending on their capabilities and strategic fit.”
For more information on this analysis, please email Anna Zanchi, Corporate Communications, at anna.zanchi@frost.com
Analysis of the Global Biosimilars Market is part of the Life Sciences Growth Partnership Service program. Frost & Sullivan’s related studies include: Analysis of European Biosimilars Market, Specialty Physicians Discuss their Opinions of the United States Biosimilars Market, Opportunity Analysis for Biosimilars – South Korea and Strategic Analysis of Indian Biosimilar Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan

New research from Frost & Sullivan reveals that the global biosimilars market earned revenue of about $1.2 billion in 2013 and could reach $24 billion in 2019.

The imminent entry of several companies, including Big Pharma, small biotech and generic participants, into the global biosimilars space will propel the market towards exponential growth, the report states. Already, Indian groups such as Dr. Reddy’s Laboratories, Biocon and Reliance Life Sciences are making a concerted effort to enter the European market; although they have not yet penetrated it due to the stringent regulatory pathway, new product launches are expected in the mid-term.

Biosimilar markets in countries such as the U.S. and Japan are also expected to grow exponentially with more clarity on the regulatory pathway, according to the report.

Untapped U.S. markets with a strong biosimilars pipeline as well as markets in Asia-Pacific and Latin America with a low cost of manufacturing will afford key growth opportunities.

“On one hand, the market is powering ahead regarding the strength of participants’ global expansion strategies, and, on the other, it is still beset by traditional patent-infringement issues,” said Frost & Sullivan Healthcare Senior Research Analyst K. Srinivas Sashidhar. “Moreover, the strategies adopted by innovator companies need to be taken into account. For instance, Johnson & Johnson has extended the European patent life of its innovator drug Remicade until February 2015, thereby delaying the launch of Hospira’s biosimilar monoclonal antibody (mAb) Inflectra and Celltrion’s biosimilar mAb Remsima.”

To further reduce the time to market, companies should also explore opportunities in mergers and acquisitions and alliances with companies having expertise in biosimilars manufacturing and development like Teva’s alliance with Cephalon and Lupin Pharmaceuticals’ alliance with Neuclone.

“In addition to mAbs, follitropins, interferons and low molecular weight heparins are likely to emerge in the long run,” added Sashidhar. “However, some companies may focus on specific therapeutic classes depending on their capabilities and strategic fit.”

For more information, visit http://www.lifesciences.frost.com

This entry was posted in Biotech, Europe, Global, Strategy and tagged , , . Bookmark the permalink. Trackbacks are closed, but you can post a comment.

One Comment

  1. Posted February 28, 2014 at 7:13 am | Permalink

    It’s really help a lot to understand the concept and forecast of the Global Biosimilars Market. if want to read more and comprehensive market research report on this topic please visit to http://www.jsbmarketresearch.com/healthcare-medical/r-Global-Biosimilars-Market-93556

Post a Comment

Your email is never published nor shared. Required fields are marked *

*
*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

  • Categories

  • Meta